← All Viridian Therapeutics, Inc\de filings

Viridian Therapeutics, Inc\de Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Kynam Capital Management Adjusts Viridian Therapeutics Stake
Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a change in their beneficial ownership of Viridian Therapeutics, Inc. common stock, now holding 5.7% of the class.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Deep Track Capital Discloses 3.25% Stake in Viridian Therapeutics
Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 3,592,740 shares, representing 3.25% of Viridian Therapeutics, Inc.'s common stock.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: State Street Reports 5.5% Stake in Viridian Therapeutics
State Street Corporation has disclosed beneficial ownership of 5.5% of Viridian Therapeutics Inc.'s common stock as of June 30, 2026.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Paradigm BioCapital Discloses 5.1% Stake in Viridian
Paradigm BioCapital Advisors LP and affiliates have reported a 5.1% beneficial ownership stake in Viridian Therapeutics, Inc.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Bellevue Group Discloses 6.6% Stake in Viridian Therapeutics
Bellevue Group AG and its subsidiary, Bellevue Asset Management AG, have reported a 6.6% beneficial ownership stake in Viridian Therapeutics, Inc.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Deep Track Capital Discloses 5.3% Stake in Viridian
Deep Track Capital, LP and David Kroin have filed a Schedule 13G reporting a 5.3% beneficial ownership stake in Viridian Therapeutics, Inc.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Vanguard Group Reports Zero Stake in Viridian Therapeutics
The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in Viridian Therapeutics Inc. following an internal realignment.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Kynam Capital Discloses 1.54% Stake in Viridian Therapeutics
Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang reported beneficial ownership of 1.54% of Viridian Therapeutics, Inc. common stock.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Deep Track Capital Reduces Viridian Therapeutics Stake
Deep Track Capital and affiliates have reduced their beneficial ownership in Viridian Therapeutics to 2.65%, falling below the 5% threshold.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE: Commodore Capital Reduces Stake in Viridian Therapeutics
Commodore Capital LP and Commodore Capital Master LP have reduced their beneficial ownership in Viridian Therapeutics, Inc. to 3.9% of common stock.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE 13G: Kynam Capital Management Discloses 5.76% Passive Stake in Viridian Therapeutics
Kynam Capital Management, LP, along with its affiliates, has reported a beneficial ownership of 5.76% of Viridian Therapeutics, Inc.'s common stock, totaling 4,700,000 shares, in a passive Schedule 13G filing.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE 13G: Commodore Capital Discloses 5.3% Passive Stake in Viridian Therapeutics
Commodore Capital LP and Commodore Capital Master LP have jointly disclosed a passive beneficial ownership of 5.3% in Viridian Therapeutics, Inc., totaling 4.3 million shares.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
SCHEDULE 13G/A: Venrock Healthcare Capital Partners Reduces Stake in Viridian Therapeutics Below 5%
Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of Viridian Therapeutics, Inc. common stock to 4.5% as of December 31, 2024.